Tamoxifen or aromatase inhibitors in breast cancer: Efficacy and safety

Acta Chirurgica Belgica

Volumn 107, Issue 3, 2007, Pages 240-256

  Neven, P ^a   Van Den Broecke, R ^b  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Aromastase inhibitor; Breast cancer; Chemotherapy; Oestrogen receptor; Tamoxifen

Indexed keywords

EID: 34547358191     PISSN: 00015458     EISSN: 25770160     Source Type: Journal    
DOI: 10.1080/00015458.2007.11680051     Document Type: Review

References (136)

1. YAGER J. D., DAVIDSON N. E. Oestrogen carcinogenesis in breast cancer. N Engl J Med, 2006, 354 : 270-82.
2. JORDAN V. C. Selective oestrogen receptor modulation : Concept and consequences in cancer. Cancer Cell, 2004, 5 : 207-13.
3. EARLY BREAST CANCER TRIALISTS' COLLABORATIVE GROUP. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival : an overview of the randomised trials. Lancet, 2005, 365 : 1687-717.
4. FISHER B., COSTANTINO J. P., WICKERHAM D. L. et al. Tamoxifen for the prevention of breast cancer : Current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst, 2005, 97 : 1652-62.
5. CUZICK J., FORBES J. F., SESTAK I. et al. Long-term results of tamoxifen prophylaxis for breast cancer - 96-month follow-up of the randomized IBIS-I trial. JNatl Cancer Inst, 2007, 99 : 272-82.
6. AMERICAN COLLEGE OF OBSTETRICIANS AND GYNECOLOGISTS COMMITTEE ON GYNECOLOGIC PRACTICE. ACOG committee opinion. No. 336 : Tamoxifen and uterine cancer. Obstet Gynecol, 2006, 107 : 1475-8.
7. HOLLI K., VALAVAARA R., BLANCO G. et al. Safety and efficacy results of a randomized trial comparing adjuvant toremifene and tamoxifen in postmenopausal patients with node-positive breast cancer. Finnish breast cancer group. J Clin Oncol, 2000, 18 : 3487-94,
8. SHANG Y. Molecular mechanisms of oestrogen and SERMs in endometrial carcinogenesis. Nature Reviews Cancer, 2006, 6 : 360-8.
9. ETTINGER B., BLACK D. M., MITLAK B. H. et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene : Results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA, 1999, 282 : 637-45.
10. VOOEL V. G., COSTANTINO J. P., WICKERHAM D. L. et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes : the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA, 2006, 295 : 2727-41.
11. BRAITHWAITE R. S., CHLEBOWSKI R. T., LAU J. et al. Meta-analysis of vascular and neoplastic events associated with tamoxifen. J Gen Intern Med, 2003, 18 : 937-47.
12. LI C. I., DALINO J. R., MALONE K. E. Incidence of invasive breast cancer by hormone receptor status from 1992 to 1998. J Clin Oncol, 2003, 21: 28-34.
13. 12a. RAVDIN P. M., CRONIN K. A., HOWLADER N. et al. The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med, 2007, 356 : 1670-4.
14. 12b. JEMAL A., WARD E., THUN M. J. Recent trends in breast cancer incidence rates by age and tumor characteristics among U.S. women. Breast Cancer Res, 2007 May, 3 : 9 E-pub.
15. MCPHERSON K., STEEL C. M., DIXON J. M. ABC of breast diseases. Breast cancer-epidemiology, risk factors, and genetics. BMJ, 2000, 321: 624-8.
16. COLDITZ G. A., ROSNER B. Cumulative risk of breast cancer to age 70 years according to risk factor status : data from the Nurses' Health Study. Am J Epidemiol, 2000, 152 : 950-64.
17. AHLGREN M., MELBYE M., WOHLFAHRT J., SORENSEN T. I. Growth patterns and the risk of breast cancer in women. N Engl J Med, 2004, 351 : 1619-26.
18. RINALDI S., KEY T. J., PEETERS P. H. et al. Anthropometric measures, endogenous sex steroids and breast cancer risk in post-menopausal women : a study within the EPIC cohort. Int J Cancer, 2006, 118 : 2832-9.
19. KAAKS R., RINALDI S., KEY T. J. et al. Postmenopausal serum androgens, oestrogens and breast cancer risk : the European prospective investigation into cancer and nutrition. Endocr Relat Cancer, 2005, 12 : 1071-82.
20. ANDERSON W. F., MATSUNO R. Breast cancer heterogeneity : A mixture of at least two main types ? J Natl Cancer Inst, 2006, 98 : 948-51.
21. FINCH A., BEINER M., LUBINSKI J. et al. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. JAMA, 2006, 296 : 185-92.
22. GRONWALD J., TUNG N., FOULKES W. D. et al. Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers : an update. Int J Cancer, 2006, 118 : 2281-4.
23. ALTHUIS M. D., FERGENBAUM J. H., GARCIA- CLOSAS M., BRINTON L. A., MADIGAN M. P., SHERMAN M. E. Etiology of hormone receptor-defined breast cancer : a systematic review of the literature. Cancer Epidemiol Biomarkers P rev, 2004, 13 : 1558-68. Review.
24. COLDITZ G. A., ROSNER B., CHEN W. Y., HOLMES M. D., HANKINSON S. E. Risk factors for breast cancer according to oestrogen and progesterone receptor status. J Natl Cancer Inst, 2004, 96 : 218-28.
25. BERRINO F., PASANISI P., BELLATI C. et al. Serum testosterone levels and breast cancer recurrence. Int J Cancer, 2005, 113 : 499-502.
26. KROENKE C. H., CHEN W. Y., ROSNER B., HOLMES M. D. Weight, weight gain, and survival after breast cancer diagnosis. J Clin Oncol, 2005, 23 : 1370-8.
27. SIMPSON E. R. Sources of oestrogen and their importance. J Steroid Biochem Mol Biol, 2003, 86 : 225-30.
28. DAVIDSON N. E., O'NEILL A. M., VUKOV A. M. et al. Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer : results from INT 0101 (E5188). J Clin Oncol, 2005, 23 : 5973-82.
29. COLLEONI M., GELBER S., GOLDHIRSCH A. et al. Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer : International Breast Cancer Study Group Trial 13-93. J Clin Oncol, 2006, 24 : 1332-41.
30. EARLY BREAST CANCER TRIALISTS' COLLABORATIVE GROUP. Ovarian ablation in early breast cancer : Overview of the randomized trials. Lancet, 1996, 348 : 1189-96.
31. KLUN J. G., BBEX L. V., MAURIAC L. et al. Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer : a randomized study. J Natl Cancer Inst, 2000, 92 : 903-11.
32. KLIJN J. G., BLAMEY R. W., BOCCARDO F. et al. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer : a meta-analysis of four randomized trials. J Clin Oncol, 2001, 19 : 343-53.
33. BAUM M., HACKSHAW A., HOUGHTON L. et al. Adjuvant goserelin in pre-menopausal women with early breast cancer : Results from the ZIPP study. Ear J Cancer, 2006, 42 : 895-904.
34. Adjuvant Breast Cancer Trials Collaborative Group. Ovarian ablation or suppression in premenopausal early breast cancer : results from the international adjuvant breast cancer ovarian ablation or suppression randomized trial. J Natl Cancer Inst, 2007, 99 : 516-25.
35. GOLDHIRSCH A., GELBER R. D., YOTHERS G. et al. Adjuvant therapy for very young women with breast cancer : The need for tailored treatments. J Natl Cancer Inst Monogr, 2001, 30 : 44-51.
36. CUZICK J. et al. The impact of LHRH agonists on breast cancer recurrence and mortality : an overview of the randomized trials. Breast Cancer Res Treat, 2006, 100 : S1 Abstr. 15.
37. AEBI S., GELBER S., CASTIGLIONE-G ERTSCH M. et al. Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer ? Lancet, 2000, 355 : 1869-74.
38. JONAT W., PRITCHARD K. I., SAINSBURY R., KLIJN J. G. Trends in endocrine therapy and chemotherapy for early breast cancer : a focus on the premenopausal patient. J Cancer Res Clin Oncol, 2006, 132 : 275-86.
39. WILDIERS H., BRAIN E. G. Adjuvant chemotherapy in elderly patients with breast cancer : where are we ? Curr Opin Oncol, 2005, 17 : 566-72. Review.
40. ALBAIN K., BARLOW W., O'MALLEY F. et al. For the Breast Cancer Intergroup of North America Concurrent (CAFT) versus sequential (CAF-T) chemohormonal therapy (cyclophosphamide, doxorubicin, 5-fluoro-uracil, tamoxifen) versus T alone for post-menopausal, node-positive, oestrogen (ER) and/or progesterone (PgR) receptor-positive breast cancer : mature outcomes and new biologic correlates on phase III intergroup trial 0100 (SWOG-8814). Breast Cancer Res Treat, 2004, 88 (Suppl 1) : Abstr. 37.
41. VIALE G., GELBER R. D., MASTROPASQUA M. G. et al. Chemoendocrine effects of adjuvant therapies for postmenopausal node-negative breast cancer according to ER, PgR, and Her2 assessed centrally. Breast Cancer Res Treat, 2003, 82 (Suppl 1) : S16-S17.
42. PAIK S., TANG G., SHAK S. et al. Gene expression and benefit of chemotherapy in women with node-negative, oestrogen receptor-positive breast cancer. J Clin Oncol, 2006, 24 : 3726-34.
43. BUYSE M., LOI SHERENE., VAN 'T VEEL L. et al. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst, 2006, 98 : 1183-92.
44. GOLDHIRSCH A., CLICK J. H., GELBER R. D., COATES A. S., THÜRUMANN B., SENN H. J. Meeting highlights : international expert consensus on the primary therapy of early breast cancer, 2005. Ann Oncol, 2005, 16 : 1569-83.
45. HOWELL A., CUZICK J., BAUM M. et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet, 2005, 365 : 60-2.44.
46. DOWSETT M., CUZICK J., WALE C., HOWELL T., HOUGHTON J., BAUM M. Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status : a hypothesis-generating study. J Clin Oncol, 2005, 23 : 7512-7.
47. THE BREAST INTERNATIONAL GROUP (BIG) 1-98 COLLABORATIVE GROUP. A comparison of letrozole and tamoxifen in post-menopausal women with early breast cancer. N Engl J Med, 2005, 353 : 2747-57.
48. COATES A. S., KSHAVIAH A., THURLIMAN B. et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer : update of study BIG 1-98. J Clin Oncol, 2007, 25 : 486-92.
49. VIALE G., REGAN M., DELL'ORTO P. et al. Central review of ER, PgR and HER-2 in BIG 1-98 evaluating letrozole vs. tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. Proceedings SABCS, 2005. Abstr. 44.
50. JAKESZ R., GNANT M., GREIL R. et al. The benefits of sequencing adjuvant tamoxifen and anastrozole in postmenopausal women with hormone-responsive early breast cancer : a 5 year-analysis of ABCSG Trial 8. Proceedings SABCS, 2005. Abstr. 13.
51. JAKESZ R., JONAT W., GNANT M. et al. Switching postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen : combined results of ABCSG trial 8 and ARNO 95 trial. Lancet, 2005, 366 : 455-62.
52. BOCCARDO F., RUBAGOTTI A., PUNTONI M. et al. Switching to anastrozole versus continued tamoxifen treatment for early breast cancer : preliminary results of the Italian Tamoxifen Anastrozole Trial. J Clin Oncol, 2005, 23 : 5138-47.
53. JONAT W., GNANT M., BOCCARDO F. et al. Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer : a meta-analysis. Lancet Oncol, 2006, 7 : 991-6.
54. COOMBES R. C., HALL E., SNOWDON C. F. et al. The IBS : a randomzed trial in postmenopausal patients with early breast cancer who remain disease-free after two or three years of tamoxifen. An updated survival analysis. Breast Cancer Res Treat, 2004, 88 S 1 : Abstr. 3.
55. COOMBES R. C., HALL E., GIBSON L. J. et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in post-menopausal women with primary breast cancer. N Engl J Med, 2004, 350 : 1081-92.
56. COOMBES C., KILBURN L. S., SNOWDON C. S. et al. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study) : a randomised controlled trial. Lancet, 2007, 369 : 559-70.
57. WINER E. P., HUDIS C., BURSTEIN H. J. et al. ASCO technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer : status report 2004. J Clin Oncol, 2005, 23 : 619-29.
58. PUNGLIA R. S., KUNTZ K. M., WINER E. P. et al. Optimizing adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer : A decision analysis. J Clin Oncol, 2005, 23 : 5178-87.
59. CUZICK J., HOWELL A. Optimal timing of the use of an aromatase inhibitor in the adjuvant treatment of postmenopausal hormone receptor - positive breast cancer. Proc Am Soc Clin Oncol, 2005, 23 : 43s Abstr. 658.
60. FISHER B., DIONAM J., BRYANT J., WOLMARK N. Five versus more than five years of tamoxifen for lymph node-negative breast cancer : Updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst, 2001, 93 : 684-90.
61. GOSS P. E., INGLE J. N., MARTINO S. et al. A randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer : updated findings from NCIC CTG MA.17. J Natl Cancer Inst, 2005, 97 : 1262-71.
62. JAKESZ R. et al. Extended adjuvant treatment with anastrozole : results from the Austrian Breast and Colorectal Cancer Study Group Trial 6a (ABCSG-6a). Proc Am Soc Clin Oncol, 2005, 23 : 10s.
63. MAMOUNAS E., JEONG J.-H., WICKERHAM L. et al. Benefit from exemestane as extended adjuvant therapy after 5 years of tamoxifen : intent-to-treat analysis of NSABP B-33. Breast Cancer Res Treat, 2006, 100 S1, Abstr. 49.
64. INOLE J. N., TU D., PATER D. L. et al. Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA. 17 extended adjuvant therapy trial. Breast Cancer Res Treat, 2006, 99: 295-300.
65. DOWSETT M., ALLRED D. C. The relationship between quantitative ER and PgR expression and HER2 status with recurrence in the ATAC trial. Breast Cancer Res Treat, 2006, 100 S1, Abstr. 48.
66. POWLES T. J., HICKISH T., KANIS J. A., TIDY A., ASHLEY S. Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and post-menopausal women. J Clin Oncol, 1996, 14 : 78-84.
67. MCCLOSKEY E., HANNON R., LAKNER G., CLACK G., MIYAMOTO A., EASTELL R. The letrozole (L), exemestane (E), and anastrozole (A) pharmacodynamics (LEAP) trial : A direct comparison of bone biochemical measurements between aromatase inhibitors (Als) in healthy postmenopausal women. J Clin Oncol, 2006, ASCO Annual Meeting Proceedings Part I. Vol 24, 18S : Abstr. 555.
68. LØNNING P. E., GEISLER J., KRAG L. E. et al. The effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer. J Clin Oncol, 2005, 23: 1-12.
69. GEISLER J., LØNNING P. E., KRAG L. E. et al. Changes in bone and lipid metabolism in postmenopausal women with early breast cancer after terminating 2-year treatment with exemestane : A randomised, placebo-controlled study. Eur J Cancer, 2006, Sept 8. Available on line.
70. PEREZ E. A., JOSSE R. G., PRITCHARD K. I. et al. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen : a companion study to NCIC CTG MA. 17. J Clin Oncol, 2006, 24 : 3629-35.
71. LOVE R. R., WIEBE D. A., FEYZI J. M., NEWCOMB P. A., CHAPPELL R. J. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women after 5 years of treatment. J Natl Cancer Inst, 1994, 86 : 1534-9.
72. WALSH B. W., KULLER L. H., WILD R. A. et al. Effects of raloxifene on serum lipids and coagulation factors in healthy post-menopausal women. JAMA, 1998, 279 : 1445-51.
73. REIS S. E., COSTANTINO J. P., WICKERHAM D. L., TAN-CHIU E., WANG J., KAVANAH M. Cardiovascular effects of tamoxifen in women with and without heart disease : breast cancer prevention trial. National Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention Trial Investigators. J Natl Cancer Inst. 2001, 93 : 16-21.
74. BARRKTT-CONNOR E., MOSCA L., COLUNS P. et al. Effects of raloxifene on cardiovascular events and breast cancer in post-menopausal women. N Engl J Med, 2006, 355 : 125-37.
75. CHLEBOWSKI R. T., ANDERSON G. L., GELLER M., COL N. Coronary heart disease and stroke with aromatase inhibitor, tamoxifen, and menopausal hormone therapy use. Clin Breast Cancer, 2006. Suppl 2 : S58-64.
76. ABRAMSON N., COSTANTINO J. P., GARBER E. et al. The effect of Factor V Leiden and prothrombin G20210 - > A mutations on thrombo-embolic risk in the national surgical adjuvant breast and bowel project breast cancer prevention trial. J Natl Cancer Inst, 2006, 98 : 904-10.
77. WASAN K. M., GOSS P. E., PRITCHARD P. H. et al. The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L). Ann Oncol, 2005, 16 : 707-15.
78. WHELAN T. J., GOSS P. E., INGLE J. N. et al. An assessment of the quality of life in MA. 17 : a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women. J Clin Oncol, 2005, 23 : 6931-40.
79. FALLOWFIELD L., CELLA D., CUZICK J. et al. The quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial. J Clin Oncol, 2004, 22 : 4261-71.
80. CELLA D., FALLOWFIELD L., BARKER P. et al. The quality of Life of Postmenopausal Women in the ATAC ("Arimidex", Tamoxifen, Alone or in Combination) Trial after Completion of 5 years' Adjuvant Treatment for Early Breast Cancer. Breast Cancer Res Treat, 2006, June 21 Available on line.
81. FALLOWFIELD L., PRICE M. H., HALL E. et al. Intergroup Exemestane Study : results of the quality of life sub-protocol. Breast Cancer Res Treat, 2004, 88 Suppl 1 : Abstr. 6.
82. MORALES L., NEVEN P., TIMMBRMAN D. et al. Acute effects of tamoxifen and third-generation aromatase inhibitors on menopausal symptoms of breast cancer patients. Anticancer Drugs, 2004, 15 : 753-60.
83. MORALES L., PANS S., PARIDAENS R. et al. Debilitating musculoskeletal pain and stiffness with letrozole and exemestane : associated tenosynovial changes on MRI. Breast Cancer Res Treat, 2006 (in press).
84. BUZDAR AU ON BEHALF OF ATAC GROUP. Clinical features of joint symptoms observed in the 'Arimidex', Tamoxifen, Alone, or in Combination (ATAC) trial. J Clin Oncology, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S : Abstr. 551.
85. ASMAR L., CANTRELL J., VUKEUA S. et al. Final analysis of a planned comparison of menopausal symptoms in 1,618 patients receiving either exemestane (E) or tamoxifen (T) in a blinded adjuvant hormonal study. Proceedings SABCS, 2005. Abstr. 2039.
86. DUFFY S. R., DLSTLER W ON BEHALF OF ATAC-TRIALISTS. Gynaecological operations during adjuvant therapy with anastrozole or tamoxifen : results from the ATAC trial. Proceedings SABCS, 2005. Abstr, 2056.
87. DUFFY S., JACKSON T. L., LANDSDOWN et al. The ATAC ('Arimidex', Tamoxifen, Alone or in Combination) adjuvant breast cancer trial : first results of the endometrial sub-protocol following 2 years of treatment. Hum Reprod, 2006, 21 : 545-53.
88. COLEMAN R. E., BANKS L. M., GIRGIS S. I. et al. Skeletal effects of exemestane in the Intergroup Exemestane Study : 2 year BMD and bone biomarker data, SABCS, 2005, Abstr. 5076.
89. COLEMAN R. E., BANKS L. M., GIRGIS S. I. et al. Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES) : a randomised controlled study. Lancet Oncol, 2007, 8 : 119-27.
90. EASTELL R., HANNON R. A., CUZICK J. et al. Effect of an aromatase inhibitor on BMD and bone turnover markers : 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230). J Bone Miner Res, 2006, 21 : 1215-23.
91. COLEMAN R. E., ON BEHALF OF THE ATAC TRIALISTS' GROUP. The effect of anastrozole on bone mineral density : 5-year results from the 'Arimidex', Tamoxifen, Alone or in Combination (ATAC) trial. J Clin Oncology, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S : Abstr. 511.
92. BRUFSKY A., HARKER W., BECK J. et al. Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J Clin Oncol, 2006 Dec 11, (Epub ahead of print).
93. GNANT M. F., MLINERITSCH B., LUSCHIN- EBENGRLTH G. et al. Zoledronic acid effectively prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer : A report from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol, 2007 Jan 3, (Epub ahead of print)
94. DEMONTY G. Treatment guidelines for adjuvant breast cancer are moving towards double standards : One for the rich and one for the poor. J Clin Oncol, 2005, 23 : 9436-7.
95. HIND D., WYLD L., REED M. W. Surgery, with or without tamoxifen, vs tamoxifen alone for older women with operable breast cancer : Cochrane review. Br J Cancer, 2007 Feb 6, (Epub ahead of print).
96. SAMTEN R. J., SANTNER S., DAVIS R., VELDHUIS J., SAMOILIK E., RUBY E. Aminoglutehimide inhibits extraglandular oestrogen production in postmenopausal women with breast carcinoma. J Clin Endocrinol Metab, 1978, 47 : 1257-1265.
97. EIRMANN W. et al. Pre-operative treatment of postmenopausal breast cancer patients with letrozole : A randomized double-blind multi-centre study. Ann Oncol, 2001, 12 : 1527-32.
98. ELUS M. J. et al. Letrozole is more effective neo-adjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, oestrogen receptor-positive primary breast cancer : evidence from a phase III randomized trial. J Clin Oncol, 2001, 19: 3808-16.
99. SMITH I. ON BEHALF OF THE IMPACT TRIALISTS. Neo-adjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen or both in combination. The IMPACT trial. J Clin Oncol, 2005, 23 : 5108-16.
100. SEMIGLAZOV V. et al. Neo-adjuvant endocrine therapy : exemestane vs tamoxifen in postmenopausal ER+ breast cancer patients (T1-4N1-2MO). Breast Cancer Res Treat, 2003, 82 (Abstr. 111).
101. DOWSETT M., EBBS S. R., DIXON J. M. et al. Biomarker changes during neo-adjuvant anastrozole, tamoxifen, or the combination : influence of hormonal status and HER-2 in breast cancer - a study from the IMPACT trialists. J Clin Oncol, 2005, 23 : 2477-92.
102. ELLIS M. J., TAO Y., YOUNG O. et al. Oestrogen-independent proliferation is present in oestrogen-receptor HER2-positive primary breast cancer after neo-adjuvant letrozole. J Clin Oncol, 2006, 24 : 3019-25.
103. CATALIOTTI L., BUZDAR A. U., NOGUCHI S. et al. Comparison of anastrozole versus tamoxifen as pre-operative therapy in post-menopausal women with hormone receptor-positive breast cancer. Cancer, 2006, 106 : 2095-103.
104. SEMIGLAZOV V. et al. The relative efficacy of neo-adjuvant endocrine therapy vs. chemotherapy in postmenopausal women with ER+ breast cancer. Proc Am Soc Clin Oncol, 2004, 23 (Abstr. 519).
105. MILANO A., DAL LAGO L., SOTIRIOU C., PICCART M., CARDOSO F. What clinicians need to know about anti-oestrogen resitance in breast cancer therapy. Eur J Cancer, 2006, 42 : 2692-705.
106. OSBORNE C. K., BARDOU V., HOPP T. A. et al. Role of the oestrogen receptor co-activator AIB1 (src-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst, 2003, 95 : 353-61.
107. GIRAULT I., LEREBOURS F., AMARIR S. et al. Expression analysis of ER-alpha co-regulators in breast carcinoma : evidence that NCOR1 expression is predictive of the response to tamoxifen. Clin Cancer Res, 2003, 9 : 1259-66.
108. SHOU J., MASSARWBH S., OSBORNE C. K. et al. Mechanisms of tamoxifen resistance : increased oestrogen receptor-HER-2/neu cross-talk in ER/HER-2 positive breast cancer. J Natl Cancer Inst, 2004, 96 : 926-35.
109. DE PLACIDO S., DE LAURENTIIS M., CARLOMAGNO C. et al. Twenty-year results of the Naples GUN randomized trial : Predictive factors of adjuvant tamoxifen efficacy in early breast cancer. Clin Cancer Res, 2003, 9 : 1039-46.
110. STAL O., BORG A., FERNO M. er al. ErbB2 status and the benefit from two or five years of adjuvant tamoxifen in postmenopausal early stage breast cancer. Ann Oncol, 2000, 11 : 1545-50.
111. DOWSETT M., HOUGHTON J., IDEN C. et al. The benefit from adjuvant tamoxifen therapy in primary breast cancer patients according to oestrogen receptor, progesterone receptor, EGF receptor and HER 2 status. Ann Oncol, 2006, 17 : 818-26.
112. HUANG I., NEVEN P., DRUKONINOEN M. et al. Association between tumour characteristics and HER-2/neu by immunohistochemistry in 1,362 women with primary operable breast cancer. J Clin Pathol, 2005, 58 : 611-6.
113. DOWSETT M., MARTIN L. A., JOHNSTON S. R., SMITH I. E, Predictors of resistance to tamoxifen. Eur J Cancer Suppl, 2004, 9 : 43-4.
114. BHARWANI L., SCHIFF R., MOHSIN S. K. et al. Inhibiting the EGFR/HER-2 pathway with gifitinib and/or trastuzumab restores tamoxifen sensitivity in HER-2 overexpressing tumours. Breast Cancer Res Treat, 2003, 82 (suppl 1) : S13 (abs. 25).
115. JOHNSTON S. R., SACCANI-JOTTI G., SMITH I. E. et al. Changes in oestrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer. Cancer Res, 1995, 55 : 3331-8.
116. MICHALIDES R., GRIEKSPOOR A., BALKENENDE A. et al. Tamoxifen resistance by a conformational arrest of the oestrogen receptor alpha after PKA activation in breast cancer. Cancer Cell, 2004, 5 : 597-605.
117. HOPP T. A., WEISS H. L., PARRA I. S. et al. Low levels of oestrogen receptor beta protein predict resistance to tumoxifen therapy in breast cancer. Clin Cancer Res, 2004, 10 : 7490-9.
118. MEIJER-VAN GELDER M. E., LOOK M. P., PETERS H. A. et al. Urokinase-type plasminogen activator system in breast cancer association with lumoxifen therapy in recurrent disease. Cancer Res. 2004, 64 : 4563-8.
119. STEARNS V., JOHNSON M. D., RAF J. M. ft al. Active tamoxifen metabolite plasma concentrations after co-administration of tamoxifen and the selective serotonin re-uptake inhibitor paroxetine. J Natl Cancer Inst, 2003, 95 : 1758-64.
120. DESTA Z., WARD B. A., SOUKHOVA N. V., FLOCKHART D. A. Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro : prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004, 310 : 1062-75.
121. JIN Y., DESTA Z., STEARNS V. et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst, 2005, 97 : 30-9.
122. PIERCE L. J., HUTCHINS L. F., GREEN S. R. et al. Sequencing of tamoxifen and radiotherapy after breast-conserving surgery in early-stage breast cancer. J Clin Oncol. 2005, 23 : 24-9.
123. PAIK S., SHAK S., TANG G. et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engt J Med, 2004, 351 : 2817-26.
124. JANSRN M. P., FOEKENS J. A.. VAN STAVBREN I. L. et al. Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling. J Clin Oncol, 2005, 23 : 732-40.
125. MA X. J., WANG Z., RYAN P. D. el al. A two-gene expression ratio predicts the clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell, 2004, 5 : 607-16.
126. ROUANET P., LINARES-CRUZ G., DRAVKT F et al. Neo-adjuvant percutaneous 4-hydroxytamoxifcn decreases breast tumoral cell proliferation : a prospective controlled randomized study comparing three doses of 4-hydroxytamoxifen gel to oral tamoxifen. J Clin Oncol, 2005, 23 : 2980-7.
127. DECKNSI A., GALLI A., VERONSEI U. HRT opposed to low-dose tamoxifen (HOT study) : rationale and design. Recent Results Cancer Res, 2003, 163 : 104-11, discussion 264-6. Review.
128. KROISS R., FENTIMAN I. S., HULMOND F. A. et al. The effect of tibolone in postmenopausal women receiving tamoxifen after surgery for breast cancer : a randomised, double-blind, placebocontrolled trial. BJOG. 2005, 112 : 228-33.
129. BKRAL V., MILLION WOMEN STUDY COLLABORATORS. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet, 2003, 362 : 419-27.
130. SESTAK I., KEALY R., EDWARDS R., FORBES J., CUZICK J. The influence of hormone replacement therapy on tamoxifen-induced vasomotor symptoms. J Clin Oncol, 2006, 24 : 3991-6.
131. DOWSETT M., CUZICK J., HOWELL A., JACKSON I. Pharmacokinetics of anastrozole and tamoxifen alone and in combination, during adjuvant endocrine therapy for early breast cancer in post-menopausal women : a sub-protocol of the "Arimidex and tamoxifen alone or in combination" (ATAC) trial. Br J Cancer, 2001, 85 : 317-24.
132. BAUM M., BUZDAR A., CUZICK J. et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer : results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer, 2003, 98 : 1802-10.
133. HUTSON P. R., LOVE R. R., HAVIGHURST T. C., ROGERS E., CLEARY J. F. The effect of exemestane on tamoxifen pharmaco-kinetics in postmenopausal women treated for breast cancer. Clin Cancer Res, 2005, 11 : 8722-7.
134. JONES A. Combining trastuzumab with hormonal therapy in breast cancer : what can be expected and why ? Ann Oncnl, 2003, 14 : 1697-704.
135. POLYCHRONIS A., SINNETT H. A., HADJIMINAS D. et al. Pre-operative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer : a double-blind placebo-controlled phase II randomised trial. Lancet Oncol, 2005, 6 : 383-91.
136. GIBSON L. J., DAWSON C., LAWRENCE D. J., BLISS J. Aromatase inhibitors for treatment of advanced breast cancer in post-menopausal women. Cochrane Database Syst Rev, 2007 Jan 24, (1) : CD003370.